The postthrombotic syndrome (PTS) is a frequent complication of deep venous thrombosis (DVT). Clinically, PTS is characterized by chronic, persistent pain, swelling, and other signs in the affected limb. Rarely, ulcers may develop. Because of its prevalence, severity, and chronicity, PTS is burdensome and costly. Preventing DVT with the use of effective thromboprophylaxis in high-risk patients and settings and minimizing the risk of ipsilateral DVT recurrence are likely to reduce the risk of development of PTS. Daily use of compression stockings after DVT might reduce the incidence and severity of PTS, but consistent and convincing data about their effectiveness are not available. Future research should focus on standardizing diagnostic criteria for PTS, identifying patients at high risk for PTS, and rigorously evaluating the role of thrombolysis in preventing PTS and of compression stockings in preventing and treating PTS. In addition, novel therapies should be sought and evaluated.
The postthrombotic syndrome (PTS) is a chronic condition that develops in 20% to 50% of patients within 1 to 2 years of symptomatic deep venous thrombosis (DVT). A severe form, which can include venous ulcers, occurs in one quarter to one third of patients with PTS.1,2 Because of its prevalence and chronicity, PTS is costly to society and is a cause of substantial patient morbidity.
In this article, we critically review the evidence informing current understanding of the pathophysiology, epidemiology, diagnosis, and management of PTS. The burden of PTS from both a patient and a societal perspective is discussed. Using standard criteria to grade the quality of the available evidence, we provide recommendations for the prevention and treatment of PTS. This article also acknowledges controversies in the field and key areas of ongoing and future research.
Clinical presentation and pathophysiology of pts
Patients with PTS complain of pain, heaviness, swelling, cramps, itching, or tingling in the affected limb. Typically, symptoms are aggravated by standing or walking and improve with rest and recumbency. On physical examination, edema, telangiectasias, hyperpigmentation, eczema, and varicose collateral veins are often present. In severe cases, lipodermatosclerosis and ulceration may result3-6 (Table 1).
The pathophysiology of PTS is incompletely understood, but it is thought that the acute thrombus itself, associated mediators of inflammation, and the process of vein recanalization in the weeks after DVT induce damage to venous valves, leading to valvular incompetence (reflux). Valvular incompetence, persistent venous obstruction, or both cause venous hypertension,6-8 which leads to edema, tissue hypoxia, and, in some cases, skin ulceration.6,7 A number of clinical studies have suggested that valvular reflux in the proximal veins, particularly the popliteal vein, is associated with clinical manifestations of PTS.9-13 Therefore, preventing valve damage and reducing venous hypertension are likely to be important in preventing PTS.
Factors that predict the development of pts after dvt
The only clearly identified risk factor for PTS is recurrent, ipsilateral DVT, which increases the risk of PTS as much as 6-fold.1,14-17 Recurrent DVT probably causes additional damage to already compromised venous valves and further venous outflow obstruction.
Characteristics of the Initial DVT
There is little correlation between the venographic severity of the initial thrombus and subsequent development of PTS.1,18 In some studies, the risk of PTS was higher in patients with proximal rather than distal (calf) DVT,19-22 while in others the site of the initial thrombus did not influence the subsequent development of PTS.1,18,23-25 In prospective studies, reported rates of PTS after distal DVT have ranged from 20% to 80%.25-31 Hence, calf DVT is associated with a significant risk of subsequent PTS.
Whether asymptomatic DVT (ie, detected by routine screening) leads to PTS is controversial. One study found that the frequency of PTS 2 to 7 years after hip or knee arthroplasty was similarly low (approximately 5%) in patients whose routine predischarge venogram showed proximal DVT, calf DVT, or no DVT.32 All patients with DVT received 6 to 12 weeks of anticoagulant therapy. Other investigators have also found low rates of PTS after asymptomatic DVT.33,34 Conversely, some groups have shown that as many as 25% to 33% of patients with asymptomatic DVT develop PTS.35,36 Differences in patient selection, study design, and definition of PTS may explain these discrepant results, but if confirmed, this would support the clinical relevance of asymptomatic DVT in studies of thromboprophylaxis37 and would provide a rationale for reducing the risk of such thrombi.38,39
In prospective studies, clinical features such as delay in initiating treatment for DVT; risk factors for thrombosis; family history of thrombosis; protein C, protein S, or antithrombin deficiency; or the presence of the lupus anticoagulant have not been found to increase the risk of developing PTS.1,14 In retrospective studies, factors predictive of PTS were increasing age, female sex, hormone therapy, varicose veins, abdominal surgery, and increased body mass index.40,41
There is no gold standard test for the diagnosis of PTS. In patients with objectively confirmed DVT and a typical clinical presentation, PTS is usually the correct diagnosis. As it usually takes 3 to 6 months after acute DVT for the initial pain and swelling to resolve, a diagnosis of PTS should be deferred until after this time. Objective evidence of venous valvular incompetence by Doppler ultrasound or by plethysmography helps to confirm the diagnosis in symptomatic patients.10,11,20,25,42 However, a diagnosis of PTS should not be made in the absence of clinical symptoms; while most patients with symptomatic PTS have valvular incompetence, many with valvular incompetence do not have PTS.43
Three clinical scales for the diagnosis of PTS are available32,44,45 and have been used in a number of clinical studies. They are presented in detail in Table 2.32,44-46
Population-Based Studies: Incidence and Prevalence
The prevalence of PTS is influenced by the incidence of DVT. Despite advances in its prevention and treatment, the annual incidence of venous thromboembolism (VTE) (ie, DVT and pulmonary embolism) has not decreased and is 1.0 to 1.6 per 1000 persons per year, with a per-person lifetime incidence of 2% to 5%.47-51 Approximately 250 000 new cases of VTE occur in the United States each year.48 The population burden of PTS is difficult to estimate because of varying definitions of PTS and a tendency to undercode chronic conditions. In a recent study, cumulative rates of venous stasis were 7.3% at 1 year, 14.3% at 5 years, 19.7% at 10 years, and 26.8% at 20 years after DVT; the cumulative risk of ulcer was 3.7% by 20 years.19 It is estimated that more than one quarter of the at least 170 000 new cases of venous stasis syndrome per year represent PTS.52
Clinical Studies: Frequency of PTS After DVT
The frequency of PTS after objectively diagnosed DVT is difficult to estimate. Many studies have used surrogate end points such as reflux or abnormal results of venography without consideration of clinical symptoms and signs, and few have used validated PTS scores.
Nonetheless, a few prospective studies have provided key information on the frequency of PTS after symptomatic DVT. In a longitudinal cohort study of patients with a first episode of acute symptomatic DVT, Prandoni et al1 found that the cumulative incidence of PTS was 17.3% after 1 year (severe in 3%), 23% after 2 years, 28% after 5 years (severe in 9%), and 29% after 8 years. In a subsequent trial to evaluate the use of compression stockings to prevent PTS in patients with symptomatic proximal DVT, mild to moderate PTS occurred in 20% of patients assigned to stockings and in 47% of controls, and severe PTS occurred in 11% and 23%, respectively.2 The frequency of PTS in the stockings group was similar to that in the study by Prandoni et al, in which all patients were encouraged to wear compression stockings. In both studies, most cases of PTS occurred within 2 years of DVT. In contrast, in a recent study by Ginsberg and colleagues,53 27% of patients (none of whom used stockings) had developed PTS by 1 year after a first episode of symptomatic proximal DVT, but among patients who were free of PTS 1 year after DVT, only 5% subsequently developed PTS (average follow-up, 55 months). However, the Ginsberg et al study used stricter diagnostic criteria for PTS: in addition to symptoms, objective demonstration of valvular incompetence was required.
In summary, the frequency of PTS after symptomatic DVT ranges from 15% to 50%. In most cases, PTS develops within 1 to 2 years after DVT. Severe PTS occurs in 5% to 10% of patients after DVT. Table 3 provides a synopsis of prospective studies of the frequency of PTS after symptomatic DVT,1,2,10,20,21,23,25,27-29,53-55 and Table 4, after asymptomatic DVT.32-36,53,56,57
Although there is little direct-cost information available, PTS undoubtedly incurs high direct costs and indirect costs such as loss of productivity. A Swedish study estimated that the average cost of treating PTS was US $4700, or 75% of the cost of treating the primary DVT.58 Extrapolations can be made from the costs of treating chronic venous insufficiency and venous ulcers, since a proportion of these cases represent PTS.52,59-61 In a recent Canadian study, patients with venous ulcers composed 6% of home care clientele but consumed 18% of supply expenditures, and the annual cost of their care was more than $1 million.62 The direct cost of treating chronic venous insufficiency exceeds $300 million per year in the United States,52 with similar costs in Britain, Belgium, France, Germany, Italy, and Spain.4,63-65 The indirect costs of PTS are also likely to be significant, since PTS often affects persons of working age. It is estimated that, for leg ulcers, 2 million workdays are lost annually in the United States.66
Impact of PTS on Quality of Life
For chronic conditions such as PTS, assessment of quality of life can provide important information on burden of illness.3,67,68 Despite the availability of easy-to-use, validated measures of generic quality of life,68,69 few studies have quantified the long-term impact of DVT, or of PTS, on quality of life. An early study showed that almost 90% of patients were disabled and unable to work because of leg symptoms 10 or more years after iliofemoral DVT.70 In a study of patients who had DVT 6 to 8 years earlier, those with PTS had poorer health perceptions, worse physical functioning, and more severe role limitations, as measured by the SF-36 Health Survey quality-of-life questionnaire.15 Recently, in the course of conducting the Venous Insufficiency Epidemiologic and Economic Study (VEINES), our group developed and validated the VEINES-QOL/Sym questionnaire, a venous disease–specific quality-of-life measure,71 and showed that by 2 years after DVT, patients with PTS had significantly worse quality of life than those without PTS, and scores worsened with increasing severity of PTS.72
Thromboprophylaxis. Postthrombotic syndrome can be averted with the use of thromboprophylaxis to prevent DVT in high-risk patients and settings, as recommended in regularly updated consensus guidelines.73 However, audits consistently demonstrate that thromboprophylaxis is underused.74-77 Furthermore, existing thromboprophylaxis regimens do not eliminate the risk of VTE.73 New antithrombotic drugs may be more effective than existing regimens in preventing VTE in high-risk patients.78-84 Since the publication of the last consensus guidelines in 2001,73 newer classes of drugs such as synthetic pentasaccharides have demonstrated promising results in phase 3 trials of VTE prevention when compared with conventional heparins.79-82 Unfortunately, nearly 50% of VTE events occur unpredictably and therefore cannot be prevented with thromboprophylaxis.74,85 Hence, strategies that focus on preventing the development of PTS after DVT are more feasible and more likely to be effective in reducing the burden of PTS than are attempts to prevent the index DVT. Since ipsilateral DVT recurrence is a risk factor for PTS, preventing recurrent DVT by optimizing the intensity and duration of anticoagulation for an initial DVT, taking into account the patient's risk of recurrence and of bleeding,86-88 is an important goal.
Role of Thrombolysis. The use of thrombolytic therapy in addition to heparin for the treatment of acute DVT leads to higher rates of vein patency and better preservation of valve function than does the use of heparin alone. However, there is no definitive evidence that thrombolysis leads to lower rates of PTS compared with the use of heparin and warfarin alone89 (Table 5).26,90-95 Furthermore, thrombolytic trials or registries of treated patients have tended to ignore long-term outcomes such as PTS.89,96-98 Large controlled trials of standard anticoagulation vs catheter-directed thrombolysis, which may be safer and more effective than systemic therapy,97 are required to definitively address this issue.
Elastic Compression Stockings. Graduated elastic compression stockings (ECSs) assist the calf muscle pump, reduce venous hypertension and reflux, and thereby reduce edema and improve tissue microcirculation.99-103 Knee-length and thigh-length ECSs have equal physiologic effects, but the former are easier to apply and more comfortable.104
Notwithstanding their physiologic effects, data on the clinical effectiveness of ECSs in preventing PTS are scarce and inconclusive. Evidence supporting their effectiveness comes primarily from the trial by Brandjes et al2 of 194 patients with symptomatic proximal DVT. Patients were randomly allocated to daily use of 30– to 40–mm Hg knee-length ECSs for at least 2 years, or no stocking. Use of ECSs resulted in a decrease from 47% to 20% of mild or moderate PTS, and from 23% to 11% of severe PTS, diagnosed with the scale of Villalta et al45 (see Table 2). As a result of this trial, it has become common clinical practice to prescribe ECSs for patients with DVT, particularly proximal DVT.105 However, a recent randomized trial conducted by Ginsberg and colleagues53 showed no benefit of daily ECSs in preventing or treating PTS. This study used a more specific measure of PTS than that of Brandjes et al2 (see Table 2), and control patients wore sham stockings. Because of the small number of patients with PTS, benefit (or harm) of up to 30% compared with the control group could not be excluded. These results, while not definitive, question the generalizability of the results of the Brandjes et al study, which had unusually high rates of PTS in the control group and dramatic reductions in both relative and absolute risk of PTS in the stocking group.
Stockings are difficult to apply, uncomfortable, and expensive, and require replacement every few months. Because of the uncertainty regarding their value in preventing PTS after DVT, further research on their effectiveness is required.
Available treatments for established PTS are limited. Regular use of ECSs may improve symptoms and swelling. Severe intractable PTS can be managed with long-term use of an intermittent compression extremity pump.106,107 Postthrombotic venous ulcers are managed with compression therapy, leg elevation, topical dressings, and sometimes surgery.4,108-111 Ulcers are often recalcitrant and tend to recur,109 causing pain and suffering to patients112,113 and incurring high costs to society.66,114 The short-term use of "venoactive" medications such as horse chestnut seed extract or hydroxyethyl rutosides appears to be effective in reducing symptoms of chronic venous insufficiency115,116; however, their long-term effectiveness and safety and their value in patients with PTS are unknown. There is no proven role for the long-term use of diuretics to treat PTS-related edema.
Recommendations regarding prevention and treatment of pts
The following recommendations for the prevention and treatment of PTS are based on our review of the literature. Levels of evidence, using an adaptation of the categories proposed by Guyatt et al117 in the sixth American College of Chest Physicians consensus conference on antithrombotic therapy (Table 6), are used when appropriate.
The diagnosis of PTS should primarily be based on the presence of typical symptoms and signs, since objective evidence of venous valvular incompetence has low specificity for PTS. However, the presence of valvular incompetence helps to confirm the diagnosis of PTS (and rule out other conditions) in symptomatic patients.
Prevention of the index DVT will prevent PTS.
Prevention of ipsilateral DVT recurrence is likely to decrease the risk of developing PTS and prevent worsening of PTS (grade 1C).
In patients with proximal DVT, the risk of developing PTS may be reduced with daily use of knee-length, 30– to 40–mm Hg ECSs (grade 2B).
The effects of ECSs after distal DVT and the optimal duration of ECS use are not known.
There is no convincing evidence that systemic thrombolysis prevents PTS (grades 2B and 2C). Catheter-directed thrombolysis requires further evaluation in properly designed trials before it is endorsed as being effective in reducing the risk of PTS.
Compression stockings may reduce swelling in some patients with PTS and should be tried. Their benefit in this setting is extrapolated from studies of patients with chronic venous disease4 but has not been definitively shown in the setting of PTS.
Severe, intractable PTS can be improved with long-term use of an intermittent compression extremity pump (grade 1A). There is no proven role for venoactive medications or diuretics in the management of PTS.
Further work needs to be done to increase our understanding of PTS and to test potentially effective preventive and therapeutic interventions. The frequency of PTS in different DVT patient populations (asymptomatic vs symptomatic, proximal vs distal, thrombophilia) should be evaluated in prospective studies of consecutive patients, using a systematic approach to PTS diagnosis. Enumeration of the direct and indirect costs of PTS, identification of key factors that influence costs, and quantification of the impact of PTS on quality of life will allow better estimation of its population burden and more accurate evaluation of the cost-effectiveness of various preventive and therapeutic regimens. Large-scale controlled trials are needed to evaluate the effectiveness, optimal timing, strength, and duration of use of compression stockings in preventing and treating PTS. Multicenter trials of catheter-directed thrombolysis to prevent PTS in patients with extensive proximal DVT are also required. Finally, the value of venoactive agents, diuretics, and anti-inflammatory medications should be studied.
The venous thrombosis outcomes study
The Venous Thrombosis Outcomes Study is an ongoing Canadian multicenter prospective cohort study being conducted by our group. Its objectives are to estimate the incidence and timing of PTS within 2 years after objectively confirmed DVT and to identify clinical and genetic risk factors that predict its development. Quality of life is being evaluated with the VEINES-QOL/Sym questionnaire,71 and direct and indirect costs of PTS are being quantified by means of data obtained from multiple sources (patient diaries, patient interviews, hospital chart, health insurance databases).118 This study will help to enumerate the patient and societal burden of PTS and will identify key variables that most influence quality of life and costs.
Because of its prevalence, severity, and chronicity, PTS is costly and burdensome to patients and society. It is likely to become more prevalent, since the incidence of DVT has not decreased. The availability of newer, more effective antithrombotic agents may lead to a reduction in the future incidence of DVT, and thereby PTS, in certain settings. The overall frequency of PTS after symptomatic DVT ranges from 20% to 50%; severe PTS occurs in 5% to 10% of patients with DVT. Preventing ipsilateral DVT recurrence is likely to reduce the risk of PTS. There is no proven role for thrombolysis in preventing PTS. Daily use of graduated compression stockings after DVT may reduce the risk of PTS and may prevent the worsening of established PTS. Prevention of PTS is the key to reducing its morbidity, since, at present, treatment options for PTS are extremely limited.
Corresponding author: Susan R. Kahn MD, MSc, FRCPC, Department of Medicine, McGill University, Center for Clinical Epidemiology & Community Studies, Sir Mortimer B. Davis Jewish General Hospital, 3755 Cote Ste Catherine, Room A-127, Montreal, Quebec, Canada H3T 1E2 (e-mail: susan.kahn@mcgill.ca).
Accepted for publication January 24, 2003.
This work was supported in part by an unrestricted educational grant from Organon-Sanofi Synthelabo. Dr Kahn is a recipient of a Clinical Research Scientist Award from the Fonds de la Recherche en Santé du Québec, Montreal. Dr Ginsberg is a recipient of a Career Investigator Award from the Heart and Stroke Foundation of Ontario, Toronto, and a Research Chair from the Canadian Institutes of Health Research/AstraZeneca, Ottawa, Ontario.
We thank Joan Sobel, PhD, for her help with development of the tables.
1.Prandoni
PLensing
AWCogo
A
et al. The long-term clinical course of acute deep venous thrombosis.
Ann Intern Med. 1996;1251- 7
PubMedGoogle ScholarCrossref 2.Brandjes
DPMBüller
HRHeijboer
H
et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.
Lancet. 1997;349759- 762
PubMedGoogle ScholarCrossref 3.Kahn
SRSolymoss
SLamping
DLAbenhaim
L Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life.
J Gen Intern Med. 2000;15425- 429
PubMedGoogle ScholarCrossref 4.Kurz
XKahn
SRAbenhaim
L
et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management: summary of an evidence-based report of the VEINES task force.
Int Angiol. 1999;1883- 102
PubMedGoogle Scholar 7.Ackroyd
JSBrowse
NL The investigation and surgery of the post-thrombotic syndrome.
J Cardiovasc Surg (Torino). 1986;275- 16
PubMedGoogle Scholar 9.Markel
AManzo
RABergelin
ROStrandness
DE
Jr Valvular reflux after deep vein thrombosis: incidence and time of occurrence.
J Vasc Surg. 1992;15377- 382
PubMedGoogle ScholarCrossref 10.Franzeck
UKSchalch
IBollinger
A On the relationship between changes in the deep veins evaluated by duplex sonography and the postthrombotic syndrome 12 years after deep vein thrombosis.
Thromb Haemost. 1997;771109- 1112
PubMedGoogle Scholar 11.Franzeck
UKSchalch
IJäger
KASchneider
EGrimm
JBollinger
A Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study).
Circulation. 1996;9374- 79
PubMedGoogle ScholarCrossref 12.Lindhagen
ABergqvist
DHallböök
TEfsing
HO Venous function five to eight years after clinically suspected deep venous thrombosis.
Acta Med Scand. 1985;217389- 395
PubMedGoogle ScholarCrossref 13.Haenen
JHJanssen
MCvan Langen
H
et al. The postthrombotic syndrome in relation to venous hemodynamics, as measured by means of duplex scanning and strain-gauge plethysmography.
J Vasc Surg. 1999;291071- 1076
PubMedGoogle ScholarCrossref 14.Prandoni
PVillalta
SBagatella
P
et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients.
Haematologica. 1997;82423- 428
PubMedGoogle Scholar 16.McColl
MDEllison
JGreer
IATait
RCWalker
ID Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism.
Br J Haematol. 2000;108272- 274
PubMedGoogle ScholarCrossref 17.Saarinen
JSisto
TLaunkka
JSalenius
J-PTarkka
M Late sequelae of acute deep venous thrombosis: evaluation five and ten years after.
Phlebology. 1995;10106- 109
Google Scholar 18.Browse
NLClemenson
GThomas
ML Is the postphlebitic leg always postphlebitic? relation between phlebographic appearances of deep-vein thrombosis and late sequelae.
BMJ. 1980;2811167- 1170
PubMedGoogle ScholarCrossref 19.Mohr
DNSilverstein
MDHeit
JAPetterson
TMO'Fallon
WMMelton III
LJ The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study.
Mayo Clin Proc. 2000;751249- 1256
PubMedGoogle ScholarCrossref 20.Meissner
MHCaps
MTZierler
BK
et al. Determinants of chronic venous disease after acute deep venous thrombosis.
J Vasc Surg. 1998;28826- 833
PubMedGoogle ScholarCrossref 21.Monreal
MMartorell
ACallejas
JM
et al. Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study.
J Intern Med. 1993;233233- 238
PubMedGoogle ScholarCrossref 22.Lindner
DJEdwards
JMPhinney
ESTaylor
LM
JrPorter
JM Long-term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis.
J Vasc Surg. 1986;4436- 442
PubMedGoogle ScholarCrossref 23.Strandness
DE
JrLanglois
YCramer
MRandlett
AThiele
BL Long-term sequelae of acute venous thrombosis.
JAMA. 1983;2501289- 1292
PubMedGoogle ScholarCrossref 25.Kakkar
VVLawrence
D Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis: a prospective study.
Am J Surg. 1985;15054- 63
PubMedGoogle Scholar 26.Schulman
SGranqvist
SJuhlin-Dannfelt
ALockner
D Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase.
Acta Med Scand. 1986;219349- 357
PubMedGoogle ScholarCrossref 27.Masuda
EMKessler
DMKistner
RLEklof
BSato
DT The natural history of calf vein thrombosis: lysis of thrombi and development of reflux.
J Vasc Surg. 1998;2867- 74
PubMedGoogle ScholarCrossref 28.Saarinen
JKallio
TLehto
MHiltunen
SSisto
T The occurrence of the post-thrombotic changes after an acute deep venous thrombosis: a prospective two-year follow-up study.
J Cardiovasc Surg (Torino). 2000;41441- 446
PubMedGoogle Scholar 29.Haenen
JHWollersheim
HJanssen
MC
et al. Evolution of deep venous thrombosis: a 2-year follow-up using duplex ultrasound scan and strain-gauge plethysmography.
J Vasc Surg. 2001;34649- 655
PubMedGoogle ScholarCrossref 30.Meissner
MHCaps
MTBergelin
ROManzo
RAStrandness
DE
Jr Early outcome after isolated calf vein thrombosis.
J Vasc Surg. 1997;26749- 756
PubMedGoogle ScholarCrossref 31.McLafferty
RBMoneta
GLPassman
MABrant
BMTaylor
LM
JrPorter
JM Late clinical and hemodynamic sequelae of isolated calf vein thrombosis.
J Vasc Surg. 1998;2750- 57
PubMedGoogle ScholarCrossref 32.Ginsberg
JSGent
MTurkstra
F
et al. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study.
Arch Intern Med. 2000;160669- 672
PubMedGoogle ScholarCrossref 33.Andersen
MWille-Jørgensen
P Late complications of asymptomatic deep venous thrombosis.
Eur J Surg. 1991;157527- 530
PubMedGoogle Scholar 34.Warwick
DPerez
JVickery
CBannister
G Does total hip arthroplasty predispose to chronic venous insufficiency?
J Arthroplasty. 1996;11529- 533
PubMedGoogle ScholarCrossref 35.McNally
MAMcAlinden
MGO'Connell
BMMollan
RA Postphlebitic syndrome after hip arthroplasty: 43 patients followed at least 5 years.
Acta Orthop Scand. 1994;65595- 598
PubMedGoogle ScholarCrossref 36.Siragusa
SBeltrametti
CBarone
MPiovella
F Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombosis: results of a transverse epidemiologic study [in Italian].
Minerva Cardioangiol. 1997;4557- 66
PubMedGoogle Scholar 37.Heit
JAElliott
CGTrowbridge
AA
et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial.
Ann Intern Med. 2000;132853- 861
PubMedGoogle ScholarCrossref 38.Hull
RDPineo
GFStein
PD
et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.
Ann Intern Med. 2001;135858- 869
PubMedGoogle ScholarCrossref 39.Davidson
BLLensing
AW Prolonged prophylaxis after joint replacement: another step sideways?
Ann Intern Med. 2000;132914- 915
PubMedGoogle ScholarCrossref 40.Biguzzi
EMozzi
EAlatri
ATaioli
EMoia
MMannucci
PM The post-thrombotic syndrome in young women: retrospective evaluation of prognostic factors.
Thromb Haemost. 1998;80575- 577
PubMedGoogle Scholar 41.Wille-Jorgensen
PJorgensen
TAndersen
MKirchhoff
M Postphlebitic syndrome and general surgery: an epidemiologic investigation.
Angiology. 1991;42397- 403
PubMedGoogle ScholarCrossref 42.Killewich
LABedford
GRBeach
KWStrandness
DE
Jr Spontaneous lysis of deep venous thrombi: rate and outcome.
J Vasc Surg. 1989;989- 97
PubMedGoogle ScholarCrossref 43.Milne
AAStonebridge
PABradbury
AWRuckley
CV Venous function and clinical outcome following deep vein thrombosis.
Br J Surg. 1994;81847- 849
PubMedGoogle ScholarCrossref 44.Porter
JMMoneta
GLInternational Consensus Committee on Chronic Venous Disease, Reporting standards in venous disease: an update.
J Vasc Surg. 1995;21635- 645
PubMedGoogle ScholarCrossref 45.Villalta
SBagatella
PPiccioli
ALensing
AWAPrins
MHPrandoni
P Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome [abstract 158].
Haemostasis. 1994;24(suppl 1)157
Google Scholar 46.Rutherford
RBPadberg
FT
JrComerota
AJKistner
RLMeissner
MHMoneta
GL Venous severity scoring: an adjunct to venous outcome assessment.
J Vasc Surg. 2000;311307- 1312
PubMedGoogle ScholarCrossref 47.Coon
WWWillis III
PWKeller
JB Venous thromboembolism and other venous disease in the Tecumseh community health study.
Circulation. 1973;48839- 846
PubMedGoogle ScholarCrossref 48.Anderson
FA
JrWheeler
HBGoldberg
RJ
et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study.
Arch Intern Med. 1991;151933- 938
PubMedGoogle ScholarCrossref 49.Silverstein
MDHeit
JAMohr
DNPetterson
TMO'Fallon
WMMelton III
LJ Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.
Arch Intern Med. 1998;158585- 593
PubMedGoogle ScholarCrossref 50.Heit
JASilverstein
MDMohr
DN
et al. The epidemiology of venous thromboembolism in the community.
Thromb Haemost. 2001;86452- 463
PubMedGoogle Scholar 51.Nordström
MLindblad
BBergqvist
DKjellström
T A prospective study of the incidence of deep-vein thrombosis within a defined urban population.
J Intern Med. 1992;232155- 160
PubMedGoogle ScholarCrossref 52.Heit
JARooke
TWSilverstein
MD
et al. Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study.
J Vasc Surg. 2001;331022- 1027
PubMedGoogle ScholarCrossref 53.Ginsberg
JSHirsh
JJulian
J
et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study.
Arch Intern Med. 2001;1612105- 2109
PubMedGoogle ScholarCrossref 54.Johnson
BFManzo
RABergelin
ROStrandness
DE
Jr Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up.
J Vasc Surg. 1995;21307- 312
PubMedGoogle ScholarCrossref 55.AbuRahma
AFStickler
DLRobinson
PA A prospective controlled study of the efficacy of short-term anticoagulation therapy in patients with deep vein thrombosis of the lower extremity.
J Vasc Surg. 1998;28630- 637
PubMedGoogle ScholarCrossref 56.Francis
CWRicotta
JJEvarts
CMMarder
VJ Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty.
Clin Orthop. July1988;232271- 278
PubMedGoogle Scholar 57.Mudge
MLeinster
SJHughes
LE A prospective 10-year study of the post-thrombotic syndrome in a surgical population.
Ann R Coll Surg Engl. 1988;70249- 252
PubMedGoogle Scholar 58.Bergqvist
DJendteg
SJohansen
LPersson
UÖdegaard
K Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden.
Ann Intern Med. 1997;126454- 457
PubMedGoogle ScholarCrossref 59.Scott
TELaMorte
WWGorin
DRMenzoian
JO Risk factors for chronic venous insufficiency: a dual case-control study.
J Vasc Surg. 1995;22622- 628
PubMedGoogle ScholarCrossref 60.Hafner
JKuhne
ASchar
B
et al. Factor V Leiden mutation in postthrombotic and non-postthrombotic venous ulcers.
Arch Dermatol. 2001;137599- 603
PubMedGoogle Scholar 61.Gaber
YSiemens
HJSchmeller
W Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Br J Dermatol. 2001;144546- 548
PubMedGoogle ScholarCrossref 62.Harrison
MBGraham
IDFriedberg
ELorimer
EOttawa-Carleton Regional Leg Ulcer Team, A regional planning study: assessing the population with leg and foot ulcers.
Can Nurse. 2001;9718- 23
PubMedGoogle Scholar 63.Bosanquet
N Costs of venous ulcers: from maintenance therapy to investment programmes.
Phlebology. 1992;7(suppl 1)44- 46
Google Scholar 64.Van den Oever
RHepp
BDebbaut
BSimon
I Socio-economic impact of chronic venous insufficiency: an underestimated public health problem.
Int Angiol. 1998;17161- 167
PubMedGoogle Scholar 65.Abenhaim
LKurz
XVEINES Group, The VEINES study (VEnous Insufficiency Epidemiologic and Economic Study): an international cohort study on chronic venous disorders of the leg.
Angiology. 1997;4859- 66
PubMedGoogle ScholarCrossref 66.Phillips
TStanton
BProvan
ALew
R A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications.
J Am Acad Dermatol. 1994;3149- 53
PubMedGoogle ScholarCrossref 67.Lamping
DL Measuring health-related quality of life in venous disease: practical and scientific considerations.
Angiology. 1997;4851- 57
PubMedGoogle ScholarCrossref 68.Patrick
DLDeyo
RA Generic and disease-specific measures in assessing health status and quality of life.
Med Care. 1989;27(3, suppl)S217- S232
PubMedGoogle ScholarCrossref 69.Ware
JKosinski
MKeller
SD SF-36 ® Physical and Mental Health Summary Scales: A User's Manual. Boston, Mass Health Institute, New England Medical Center1994;
70.O'Donnell
TF
JrBrowse
NLBurnand
KGThomas
ML The socioeconomic effects of an iliofemoral venous thrombosis.
J Surg Res. 1977;22483- 488
PubMedGoogle ScholarCrossref 71.Lamping
DLSchroter
SKurz
XKahn
SRAbenhaim
L Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life.
J Vasc Surg. 2003;37410- 419
PubMedGoogle ScholarCrossref 72.Kahn
SRHirsch
AShrier
I Effect of post-thrombotic syndrome on health-related quality of life after deep venous thrombosis.
Arch Intern Med. 2002;1621144- 1148
PubMedGoogle ScholarCrossref 74.Arnold
DMKahn
SRShrier
I Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines.
Chest. 2001;1201964- 1971
PubMedGoogle ScholarCrossref 75.Goldhaber
SZVisani
LDe Rosa
M Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).
Lancet. 1999;3531386- 1389
PubMedGoogle ScholarCrossref 76.Stratton
MAAnderson
FABussey
HI
et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients.
Arch Intern Med. 2000;160334- 340
PubMedGoogle ScholarCrossref 77.Bratzler
DWRaskob
GEMurray
CKBumpus
LJPiatt
DS Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting.
Arch Intern Med. 1998;1581909- 1912
PubMedGoogle ScholarCrossref 78.Turpie
AGGGallus
ASHoek
JAPentasaccharide Investigators, A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
N Engl J Med. 2001;344619- 625
PubMedGoogle ScholarCrossref 79.Turpie
AGGBauer
KAEriksson
BILassen
MR Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
Lancet. 2002;3591721- 1726
PubMedGoogle ScholarCrossref 80.Lassen
MRBauer
KAEriksson
BITurpie
AGG Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Lancet. 2002;3591715- 1720
PubMedGoogle ScholarCrossref 81.Eriksson
BIBauer
KALassen
MRTurpie
AGG Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
N Engl J Med. 2001;3451298- 1304
PubMedGoogle ScholarCrossref 82.Bauer
KAEriksson
BILassen
MRTurpie
AGG Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
N Engl J Med. 2001;3451305- 1310
PubMedGoogle ScholarCrossref 83.Heit
JAColwell
CWFrancis
CW
et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Arch Intern Med. 2001;1612215- 2221
PubMedGoogle ScholarCrossref 84.Lee
AAgnelli
GBüller
H
et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.
Circulation. 2001;10474- 78
PubMedGoogle ScholarCrossref 85.Cogo
ABernardi
EPrandoni
P
et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients.
Arch Intern Med. 1994;154164- 168
PubMedGoogle ScholarCrossref 86.Kearon
CGent
MHirsh
J
et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
N Engl J Med. 1999;340901- 907
PubMedGoogle ScholarCrossref 87.Schulman
S Optimal duration of oral anticoagulant therapy in venous thromboembolism.
Thromb Haemost. 1997;78693- 698
PubMedGoogle Scholar 89.Wells
PSForster
AJ Thrombolysis in deep vein thrombosis: is there still an indication?
Thromb Haemost. 2001;86499- 508
PubMedGoogle Scholar 90.Schweizer
JKirch
WKoch
R
et al. Short- and long-term results after thrombolytic treatment of deep venous thrombosis.
J Am Coll Cardiol. 2000;361336- 1343
PubMedGoogle ScholarCrossref 91.Elliot
MSImmelman
EJJeffery
P
et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial.
Br J Surg. 1979;66838- 843
PubMedGoogle ScholarCrossref 92.Arnesen
HHøiseth
ALy
B Streptokinase of heparin in the treatment of deep vein thrombosis: follow-up results of a prospective study.
Acta Med Scand. 1982;21165- 68
PubMedGoogle ScholarCrossref 93.Turpie
AGLevine
MNHirsh
J
et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis: results of a randomized trial.
Chest. 1990;97(4, suppl)172S- 175S
PubMedGoogle Scholar 94.Common
HHSeaman
AJRösch
JPorter
JMDotter
CT Deep vein thrombosis treated with streptokinase or heparin: follow-up of a randomized study.
Angiology. 1976;27645- 654
PubMedGoogle ScholarCrossref 95.Schulman
SLockner
DGranqvist
SBratt
GPaul
CNyman
D A comparative randomized trial of low-dose versus high-dose streptokinase in deep vein thrombosis of the thigh.
Thromb Haemost. 1984;51261- 265
PubMedGoogle Scholar 96.Goldhaber
SZBuring
JELipnick
RJHennekens
CH Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis.
Am J Med. 1984;76393- 397
PubMedGoogle ScholarCrossref 97.Mewissen
MWSeabrook
GRMeissner
MHCynamon
JLabropoulos
NHaughton
SH Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry.
Radiology. 1999;21139- 49
PubMedGoogle ScholarCrossref 98.Goldhaber
SZMeyerovitz
MFGreen
D
et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.
Am J Med. 1990;88235- 240
PubMedGoogle ScholarCrossref 99.O'Donnell
TF
JrRosenthal
DACallow
ADLedig
BL Effect of elastic compression on venous hemodynamics in postphlebitic limbs.
JAMA. 1979;2422766- 2768
PubMedGoogle ScholarCrossref 101.Jones
NAWebb
PJRees
RIKakkar
VV A physiological study of elastic compression stockings in venous disorders of the leg.
Br J Surg. 1980;67569- 572
PubMedGoogle ScholarCrossref 102.Noyes
LDRice
JCKerstein
MD Hemodynamic assessment of high-compression hosiery in chronic venous disease.
Surgery. 1987;102813- 815
PubMedGoogle Scholar 103.Evers
EJWuppermann
T Effect of different compression therapies on the reflux in deep veins with a post-thrombotic syndrome.
Vasa. 1999;2819- 23
PubMedGoogle ScholarCrossref 104.Benkö
TCooke
EAMcNally
MAMollan
RAB Graduated compression stockings: knee length or thigh length.
Clin Orthop. February2001;383197- 203
PubMedGoogle ScholarCrossref 105.Kahn
SRElman
ERRodger
MAWells
PS Use of elastic compression stockings after deep venous thrombosis: a comparison of practices and perceptions of thrombosis physicans and patients.
J Thromb Haemost. 2003;1500- 506
Google ScholarCrossref 106.Ginsberg
JSBrill-Edwards
PKowalchuk
GHirsh
J Intermittent compression units for the postphlebitic syndrome: a pilot study.
Arch Intern Med. 1989;1491651- 1652
PubMedGoogle ScholarCrossref 107.Ginsberg
JSMagier
DMacKinnon
BGent
MHirsh
J Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study.
CMAJ. 1999;1601303- 1306
PubMedGoogle Scholar 111.Cullum
NNelson
EAFletcher
AWSheldon
TA Compression for venous leg ulcers.
Cochrane Database Syst Rev. 2001;(2)CD000265
Google Scholar 112.Krasner
D Painful venous ulcers: themes and stories about their impact on quality of life.
Ostomy Wound Manage. 1998;4438- 49
PubMedGoogle Scholar 113.Smith
JJGuest
MGGreenhalgh
RMDavies
AH Measuring the quality of life in patients with venous ulcers.
J Vasc Surg. 2000;31642- 649
PubMedGoogle ScholarCrossref 115.Diehm
CTrampisch
HJLange
SSchmidt
C Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency.
Lancet. 1996;347292- 294
PubMedGoogle ScholarCrossref 116.Pittler
MHErnst
E Horse-chestnut seed extract for chronic venous insufficiency: a criteria-based systematic review.
Arch Dermatol. 1998;1341356- 1360
PubMedGoogle ScholarCrossref 117.Guyatt
GSchuñemann
HCook
DJaeschke
RPauker
SBucher
H Grades of recommendation for antithrombotic agents.
Chest. 2001;119(1, suppl)3S- 7S
PubMedGoogle ScholarCrossref 118.Kahn
SRDucruet
TJohri
Mfor the Venous Thrombosis Outcomes (VETO) Study Investigators, Resource utilisation and loss of productivity during the 4 months following a diagnosis of deep venous thrombosis [abstract].
J Thromb Haemost. 2003;1(7, suppl 1)abstract 181.
Google Scholar